Drug Discovery World

FEBRUARY 13, 2023

Yet, the overarching outlook for SLAS2023, taking place from February 25 – March 1, 2023 in San Diego, USA, appears to be a very optimistic one, with the Innovation Accelerated theme showcasing the sector’s get-up-and-go attitude. How can technology help drug discovery research get to market faster and at optimum efficiency?

Protein Production 130

Protein Production DNA Virus Vaccine 130

Drug Discovery World

APRIL 17, 2024

DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA (regRNA) molecules control the expression of genes. JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. DS: How easy was it to transfer theoretical research into a viable business?

Science 147

Science RNA Disease Protein Expression 147

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineering 130

Engineering Therapies Protein Production Science 130

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

Drug Discovery World

NOVEMBER 30, 2023

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The presentation introduced the company’s high-throughput expression systems, its approaches to organising data and its design approaches. kb Influenza A hemagglutinin gene was used as a model system.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Agency IQ

APRIL 12, 2024

Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).

Production 40

Production FDA Therapies Biochemical Assays 40

Drug Discovery World

MARCH 6, 2024

Mutations in a gene may cause structural changes in its protein product, which can lead to a loss of function and consequently to the onset of a disease. They also involve multiple mutations in non-coding regions of DNA – the ‘dark genome’ which makes up around 98% of our DNA.

Clinical Trials 162

Clinical Trials Pharmaceutical Companies Disease Trials 162